<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937208</url>
  </required_header>
  <id_info>
    <org_study_id>ESC-130825</org_study_id>
    <nct_id>NCT01937208</nct_id>
  </id_info>
  <brief_title>Comparable Study of Different Radiation Dose in Esophageal Carcinoma</brief_title>
  <official_title>A Prospective, Randomised Phase 3 Study of High-dose Versus Standard-dose Radiation of Inoperable Esophageal Carcinoma Treated With Concurrent Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation therapy plus concurrent chemotherapy is now the standard therapy for patients with
      localized carcinoma of the esophagus selected for nonsurgical treatment. The standard
      radiation dose is 50-50.4Gy/1.8-2.0Gy/F.All of this were based on 2D radiation technology.
      Entering new century, 3D-CRT or IMRT has used on esophageal cancer. In China,the recommend
      radiation dose of concurrent chemoradiation was 60Gy. The study is a clinical phase III,
      randomized trial to compare the different radiation dose(60Gy vs 50Gy) of concurrent
      chemoradiation using 3D-CRT or IMRT in patients with unresectable esophageal carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>local control rate; relapse location; toxicity</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>radiation-related advent events</measure>
    <time_frame>at least 3 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Esophageal Carcinoma</condition>
  <arm_group>
    <arm_group_label>high-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity modulated radiation therapy in both arms</intervention_name>
    <arm_group_label>high-dose</arm_group_label>
    <arm_group_label>standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concurrent chemotherapy with radiation</intervention_name>
    <description>docetaxel plus cisplatin were used weekly in both arms</description>
    <arm_group_label>high-dose</arm_group_label>
    <arm_group_label>standard dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytologic diagnosis of esophageal carcinoma

          -  ECOG performance status 0-1

          -  Age:18-70 years

          -  Joined the study voluntarily and signed informed consent form

          -  Patients must not have received any prior anticancer therapy

          -  Unresectable disease, or refuse surgery.Stage Ⅰ-ⅣA（AJCC 2009）

          -  Target lesions can be measured according to RECIST criteria

          -  No serious system dysfunction and immuno-deficiency, Adequate organ function including
             the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet
             count ≥100x 109/L, TBIL&lt;1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN

          -  Use of an effective contraceptive for adults to prevent pregnancy

          -  Life expectancy of more than 3 months

        Exclusion Criteria:

          -  Multiple carcinomas of the esophagus,

          -  Biopsy-proven invasion of the tracheobronchial tree or tracheoesophageal fistula,

          -  Metastatic disease (M1),

          -  A primary tumor that extended to within 2 cm of the gastroesophageal junction,

          -  Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor,

          -  Concurrent pregnancy or lactation, history of a second malignancy other than
             nonmelanoma skin cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao Zheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiao zheng, MD</last_name>
    <phone>0086-571-88122078</phone>
    <email>zhengxiao@medmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ming chen, PHD</last_name>
    <phone>0086-571-88122068</phone>
    <email>chenming@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiao zheng, MD</last_name>
      <phone>0086-571-88122078</phone>
      <email>zhengxiao@medmail.com</email>
    </contact>
    <investigator>
      <last_name>ming chen, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2013</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal Carcinoma</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>radiation dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

